Certain Ordinary Shares of Kiadis Pharma N.V. are subject to a Lock-Up Agreement Ending on 31-MAY-2021. These Ordinary Shares will be under lockup for 731 days starting from 31-MAY-2019 to 31-MAY-2021. Details: The largest shareholders of the company, as well as all members of the management board and supervisory board have agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share disposals. The majority of the company shares issued to the CytoSen shareholders pursuant to the CytoSen acquisition agreement – i.e. the shares issued to CytoSen’s Executive Chairman, CEO and founders – will be subject to a lock-up by the company for a period of two years from closing, with the remainder of the shares subject to a lock-up for 180 days.